AI-driven biotech Iambic snags $100M to enter the clinic next year in HER2 field
Another AI-driven biotech has reeled in Series B funding, with Iambic Therapeutics disclosing a $100 million round a week after Evozyne nabbed $81 million. Both are working with technology and receiving capital from the computational powerhouse Nvidia.
Formerly known as Entos, the oral small molecule startup will use the funds to start its first clinical trial early next year, CEO Tom Miller told Endpoints News. Iambic had originally targeted $80 million for the round but received outsized investor interest, Miller said, noting the startup’s ability to go from program launch to IND submission in about 24 months.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.